-
公开(公告)号：US20160166541A1
公开(公告)日：2016-06-16
申请号：US15007409
申请日：2016-01-27
IPC分类号： A61K31/407 , C12Q1/68
CPC分类号： A61K31/407 , A01N43/38 , A61K31/40 , C07H21/04 , C12Q1/6883 , C12Q1/6897 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
摘要： The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
摘要翻译： 本发明涉及SCN9A中的突变引起人类先天性疼痛（CIP）的因素的发现。 本发明还涉及使用化合物小有机化合物治疗疼痛以及预测止痛剂对患者的作用的方法，例如具有功能突变增益的那些。
-
2.发明申请COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION 有权用于沉默APOLIPOPROTEIN C-III表达的组合物和方法公开(公告)号：US20120184595A1
公开(公告)日：2012-07-19
申请号：US13146394
申请日：2010-01-26
申请人： Marcia MacDonald , Amy C.H. Lee , Ian MacLachlan
发明人： Marcia MacDonald , Amy C.H. Lee , Ian MacLachlan
IPC分类号： A61K31/713 , C12N5/02 , A61P9/10 , C12N15/113 , A61P3/06
CPC分类号： C12N15/113 , A61K9/1272 , A61K9/1617 , A61K31/713 , A61K47/544 , A61K47/554 , A61K47/60 , A61K47/6907 , A61K47/6921 , B82Y5/00 , C12N2310/14 , C12N2310/321 , C12N2310/3515 , C12N2310/3521 , C12N2320/30
摘要： The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
摘要翻译： 本发明提供包含治疗性核酸的组合物，例如靶向载脂蛋白C-III（APOC3）基因表达的干扰RNA，包含治疗性核酸的一种或多种（例如，混合物）的脂质颗粒，制备脂质颗粒的方法， 以及递送和/或施用脂质颗粒的方法（例如，用于治疗脂质疾病或病症如动脉粥样硬化或血脂异常如高甘油三酯血症或高胆固醇血症）。
-
公开(公告)号：US20060166207A1
公开(公告)日：2006-07-27
申请号：US10534419
申请日：2003-11-12
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C07K14/47 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6896
摘要： Methods of utilizing a gene related to pain perception, herein dubbed HSN2, or its encoded protein, dubbed herein “sensorin,” for the screening and identification of agents for the treatment of pain, neuropathy and related disorders, especially small organic compounds, as well as methods of using these compounds to treat or otherwise ameliorate pain, neuropathy and related disorders in human patients. Novel polypeptides and polynucleotides, along with their nucleotide and amino acid sequences, are also disclosed.
摘要翻译： 用于本文称为“感染蛋白”的HSN2或其编码的蛋白质，用于筛选和鉴定用于治疗疼痛，神经病和相关病症，特别是小有机化合物的药剂的疼痛感知相关基因的方法，以及 作为使用这些化合物治疗或改善人类患者的疼痛，神经病和相关疾病的方法。 还公开了新的多肽和多核苷酸及其核苷酸和氨基酸序列。
-
4.发明申请Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof 审中-公开少年血色素沉着症基因（hfe2a），表达产物及其用途公开(公告)号：US20070166711A1
公开(公告)日：2007-07-19
申请号：US10552158
申请日：2004-04-08
申请人： Mark Samuels , Erwin Ludwig , Marcia MacDonald , Patrick Franchini , Yigal Goldberg , Rajender Kamboj , George Papanikolaou
发明人： Mark Samuels , Erwin Ludwig , Marcia MacDonald , Patrick Franchini , Yigal Goldberg , Rajender Kamboj , George Papanikolaou
IPC分类号： A61K48/00 , A61K38/40 , C12Q1/68 , G01N33/567 , A61K39/395 , C12N5/08
CPC分类号： G01N33/5023 , A61K38/40 , A61K48/00 , C07K14/47 , C12Q1/6883 , C12Q1/6897 , C12Q2600/156 , C12Q2600/158 , G01N33/5008 , G01N33/5091 , G01N2500/10 , Y10T436/143333
摘要： Polynucleotide and polypeptide sequences for HFE2A, as well as mutations associated with juvenile hemochromatosis, and methods of utilizing these for the screening and identification of agents for the treatment of diseases of iron metabolism, including small organic compounds, are disclosed along with methods of treating and/or ameliorating diseases of iron metabolism, especially in human patients are disclosed. Diagnostic compounds, kits and methods using HFE2A are also described.
摘要翻译： HFE2A的多核苷酸和多肽序列以及与幼年血色素沉着相关的突变，以及利用它们用于筛选和鉴定用于治疗铁代谢疾病（包括小有机化合物）的药剂的方法，以及治疗和 /或改善铁代谢疾病，特别是在人类患者中。 还描述了使用HFE2A的诊断化合物，试剂盒和方法。
-
公开(公告)号：US09278088B2
公开(公告)日：2016-03-08
申请号：US13860810
申请日：2013-04-11
CPC分类号： A61K31/407 , A01N43/38 , A61K31/40 , C07H21/04 , C12Q1/6883 , C12Q1/6897 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
摘要： The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
摘要翻译： 本发明涉及SCN9A中的突变引起人类先天性疼痛（CIP）的因素的发现。 本发明还涉及使用化合物小有机化合物治疗疼痛以及预测止痛剂对患者的作用的方法，例如具有功能突变增益的那些。
-
6.发明授权公开(公告)号：US09023820B2
公开(公告)日：2015-05-05
申请号：US13146394
申请日：2010-01-26
申请人： Marcia MacDonald , Amy C. H. Lee , Ian MacLachlan
发明人： Marcia MacDonald , Amy C. H. Lee , Ian MacLachlan
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , A61K9/127 , A61K9/16 , A61K31/713 , A61K47/48 , B82Y5/00 , C12N15/113
CPC分类号： C12N15/113 , A61K9/1272 , A61K9/1617 , A61K31/713 , A61K47/544 , A61K47/554 , A61K47/60 , A61K47/6907 , A61K47/6921 , B82Y5/00 , C12N2310/14 , C12N2310/321 , C12N2310/3515 , C12N2310/3521 , C12N2320/30
摘要： The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
摘要翻译： 本发明提供包含治疗性核酸的组合物，例如靶向载脂蛋白C-III（APOC3）基因表达的干扰RNA，包含治疗性核酸的一种或多种（例如，混合物）的脂质颗粒，制备脂质颗粒的方法， 以及递送和/或施用脂质颗粒的方法（例如，用于治疗脂质疾病或病症如动脉粥样硬化或血脂异常如高甘油三酯血症或高胆固醇血症）。
-
公开(公告)号：US20130210884A1
公开(公告)日：2013-08-15
申请号：US13860810
申请日：2013-04-11
IPC分类号： A61K31/407
CPC分类号： A61K31/407 , A01N43/38 , A61K31/40 , C07H21/04 , C12Q1/6883 , C12Q1/6897 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
摘要： The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
摘要翻译： 本发明涉及SCN9A中的突变引起人类先天性疼痛（CIP）的因素的发现。 本发明还涉及使用化合物小有机化合物治疗疼痛以及预测止痛剂对患者的作用的方法，例如具有功能突变增益的那些。
-
公开(公告)号：US20070212685A1
公开(公告)日：2007-09-13
申请号：US10369909
申请日：2003-02-19
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/6893 , C07H21/04 , C12Q1/68 , C12Q1/6806 , C12Q1/6809 , C12Q1/6813 , C12Q1/6827 , C12Q1/6897
摘要： The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
摘要翻译： 本发明涉及SCN9A中的突变引起人类先天性疼痛（CIP）的因素的发现。 本发明还涉及利用SCN9A基因及其表达产物的方法来筛选和鉴定对SCN9A有选择性的治疗剂，包括小的有机化合物，并且可用于治疗疼痛和其它疾病。 本发明还涉及使用这些化合物来治疗或改善这些病症的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.026 秒)
